NLRP3 and heart failure: In contrast, SGLT2 inhibitors—now widely adopted in cardiovascular medicine—demonstrate favorable effects on NLRP3 suppression, atrial structural remodeling, and arrhythmia prevention, particularly in patients with diabetes or heart failure.